T207. METABOLIC ADVERSE EFFECTS OF OFF-LABEL USE OF SECOND-GENERATION ANTIPSYCHOTICS IN THE ADULT POPULATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
Sign Up to like & getrecommendations! Published in 2020 at "Schizophrenia Bulletin"
DOI: 10.1093/schbul/sbaa029.767
Abstract: Abstract Background Second generation antipsychotics (SGAs) are approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia, bipolar disorder and treatment refractory depression. Since the late 1990’s, prescription of antipsychotics has… read more here.
Keywords: use; metabolic adverse; adverse effects; second generation ... See more keywords
The metabolic adverse effects of antipsychotic use in individuals with intellectual and/or developmental disability: A systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2022 at "Acta Psychiatrica Scandinavica"
DOI: 10.1111/acps.13484
Abstract: Individuals with intellectual and/or developmental disability (IDD) are often prescribed antipsychotics (APs). However, despite their known propensity to cause metabolic adverse effects, including weight gain, diabetes, and increased risk of cardiovascular events, there is currently… read more here.
Keywords: intellectual developmental; adverse effects; individuals intellectual; metabolic adverse ... See more keywords
Monitoring of Metabolic Adverse Effects Associated With Atypical Antipsychotics Use in an Outpatient Psychiatric Clinic
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Pharmacy Practice"
DOI: 10.1177/0897190017752712
Abstract: Background: Atypical antipsychotics are associated with metabolic complications that contribute to a higher risk of cardiovascular disease. Current evidence reveal suboptimal adherence to the complex and variable official recommendations on metabolic monitoring in the corresponding… read more here.
Keywords: atypical antipsychotics; monitoring metabolic; outpatient psychiatric; psychiatric clinic ... See more keywords
Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain
Sign Up to like & getrecommendations! Published in 2021 at "Neuropsychiatric Disease and Treatment"
DOI: 10.2147/ndt.s282856
Abstract: Purpose Cardiovascular and metabolic adverse events are costly to treat, and their incidence is increased amongst people with schizophrenia, with different rates observed for second-generation antipsychotics. To inform treatment choice, this study sought to estimate… read more here.
Keywords: treatment; adverse events; cardiovascular metabolic; weight gain ... See more keywords